Umbrella : A deployable SDN-enabled IXP switching fabric

Software Defined internet eXchange Points (SDXs) are a promising solution to the long-standing limitations and problems of interdomain routing. While proposed SDX architectures have improved the scalability of the control plane, these solutions have ignored the underlying fabric upon which they should be deployed. This work makes the case for a new fabric architecture that proposes stronger control and data plane separation

Presence of proterotheriidae (Mammalia, litopterna) in the Pleistocene of the bonaerian pampas

The fossil record of Pleistocene Proterotheriidae is scarce. It is restricted to the species Neolicaphrium recens known from Brazil, Uruguay, and Argentina, and to Uruguayodon alius, from Uruguay. Up to the date, proterotheriids are absent from the Pleistocene record of the Pampean Region. The aim of the present contribution is to report isolated remains of proterotheriids coming from Punta Indio and Punta Médanos localities, at the coast of Buenos Aires Province, Argentina. The specimens were found in the coastline and lack precise stratigraphical position. These findings indicate that Pleistocene proterotheriids were probably more diversified and geographically widespread than previously thought.O registro fóssil pleistocênico de Proterotheriidae é escasso. Se restringe às espécies Neolicaphrium recens, conhecida para o Brasil, Uruguai e Argentina, e Uruguayodon alius do Uruguai. Até o presente momento, os proteroterídeos estão ausentes no Pleistoceno da Região Pampeana da Argentina. A presente contribuição tem por objetivo reportar restos isolados de proteroterídeos provenientes das localidades de Punta Indio e Punta Médanos, região costeira da Província de Buenos Aires, Argentina. Os espécimes foram encontrados na linha de costa e carecem de contexto estratigráfico preciso. Estes achados sugerem que os proteroterídeos pleistocênicos eram possivelmente mais diversificados e mais amplamente distribuídos geograficamente do que se supunha anteriormente.Fil: Agnolin, Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Museo Argentino de Ciencias Naturales "Bernardino Rivadavia"; Argentina. Universidad Maimónides; Argentina. Fundación de Historia Natural Félix de Azara; ArgentinaFil: Chimento, Nicolás Roberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Museo Argentino de Ciencias Naturales "Bernardino Rivadavia"; ArgentinaFil: Bruyere, Marcelo R.. No especifíca

Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis

Introduction: The objective of this systematic review and meta-analysis is to systematically identify and review the efficacy of pharmacological treatments in men with osteoporosis. Methods: Medline (via Ovid) and Cochrane CENTRAL were searched up to May 2023 for any randomized controlled trial (RCT) evaluating the efficacy of osteoporotic treatment on the evolution of Bone Mineral Density (BMD) and incidence of fractures of men suffering from primary osteoporosis. If at least two studies used the same pharmacological treatment and evaluated the same outcome, a random effect model meta-analysis was applied to reported pooled mean difference (MD) and 95% confidence interval (CI). Results: From the 1,061 studies identified through bibliographic search, 21 RCTs fitted the inclusion criteria. Bisphosphonates (k = 10, n = 2992 men with osteoporosis) improved all three BMD sites compared to placebo; lumbar spine: MD + 4.75% (95% CI 3.45, 6.05); total hip: MD + 2.72% (95% CI 2.06; 3.37); femoral neck: MD + 2.26% (95% CI 1.67; 2.85). Denososumab (k = 2, n = 242), Teriparatide (k = 2, n = 309) and Abaloparatide (k = 2, n = 248) also produced significant improvement of all sites BMD compared to placebo. Romosozumab was only identified in one study and was therefore not meta-analysed. In this study, Romosozumab increased significantly BMD compared to placebo. Incident fractures were reported in 16 RCTs but only four reported fractures as the primary outcome. Treatments were associated with a lower incidence of fractures. Conclusions: Medications used in the management of osteoporosis in women appear to provide similar benefits in men with osteoporosis. Therefore, the algorithm for the management of osteoporosis in men could be similar to the one previously recommended for the management of osteoporosis in women

Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow cultures

The basic mechanisms by which strontium ranelate acts on bone are still unclear. We show that an important action of strontium salts is to block calcification in cultures of osteoblasts, the bone-forming cells. These results suggest that strontium treatment could have previously overlooked effects on bone

Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis

Osteoarthritis is a syndrome affecting a variety of patient profiles. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the European Union Geriatric Medicine Society working meeting explored the possibility of identifying different patient profiles in osteoarthritis. The risk factors for the development of osteoarthritis include systemic factors (e.g., age, sex, obesity, genetics, race, and bone density) and local biomechanical factors (e.g., obesity, sport, joint injury, and muscle weakness); most also predict disease progression, particularly joint injury, malalignment, and synovitis/effusion. The characterization of patient profiles should help to better orientate research, facilitate trial design, and define which patients are the most likely to benefit from treatment. There are a number of profile candidates. Generalized, polyarticular osteoarthritis and local, monoarticular osteoarthritis appear to be two different profiles; the former is a feature of osteoarthritis co-morbid with inflammation or the metabolic syndrome, while the latter is more typical of post-trauma osteoarthritis, especially in cases with severe malalignment. Other biomechanical factors may also define profiles, such as joint malalignment, loss of meniscal function, and ligament injury. Early- and late-stage osteoarthritis appear as separate profiles, notably in terms of treatment response. Finally, there is evidence that there are two separate profiles related to lesions in the subchondral bone, which may determine benefit from bone-active treatments. Decisions on appropriate therapy should be made considering clinical presentation, underlying pathophysiology, and stage of disease. Identification of patient profiles may lead to more personalized healthcare, with more targeted treatment for osteoarthritis

Rethinking IXPs' architecture in the age of SDN

© 2018 IEEE. Software-defined Internet eXchange points (SDXs) are a promising solution to the long-standing limitations and problems of interdomain routing. While the proposed SDX architectures have improved the scalability of the control plane, these solutions have ignored the underlying fabric upon which they should be deployed. In this paper, we present Umbrella, a software-defined interconnection fabric that complements and enhances those architectures. Umbrella is a switching fabric architecture and management approach that improves the overall robustness, limiting control plane dependence, and suitable for the topology of any existing Internet eXchange Point (IXP). We validate Umbrella through a real-world deployment on two production IXPs, TouSIX and NSPIXP-3, and demonstrate its use in practice, sharing our experience of the challenges faced

Management of osteoporosis in the elderly

n/

The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS)

\ua9 2024 The Author(s).Importance: Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists. Objective: The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia. Design: The GLIS steering committee was formed in 2019-21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70-80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached. Results: 107 participants (mean age: 54 \ub1 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on \u27general aspects of sarcopenia\u27 (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on \u27components of sarcopenia\u27 (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on \u27outcomes of sarcopenia\u27 (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as \u27components of sarcopenia\u27, whereas impaired physical performance was accepted as an \u27outcome\u27 rather than a \u27component\u27 of sarcopenia. Conclusion and relevance: The GLIS has created the first global conceptual definition of sarcopenia, which will now serve to develop an operational definition for clinical and research settings